Editorial
doi: 10.1016/j.clon.2021.06.005.
Epub 2021 Jul 1.
Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No
Affiliations
- PMID: 34218999
- DOI: 10.1016/j.clon.2021.06.005
Item in Clipboard
Editorial
Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No
Clin Oncol (R Coll Radiol).
2021 Dec.
No abstract available
Comment in
-
In Response to: 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy?' by Ostler et al. and 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No' by Macbeth and Hughes-Davies.Clin Oncol (R Coll Radiol). 2022 Apr;34(4):e169-e170. doi: 10.1016/j.clon.2022.01.041. Epub 2022 Feb 8. Clin Oncol (R Coll Radiol). 2022. PMID: 35148914 No abstract available.
Comment on
-
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.Lancet Oncol. 2021 Jan;22(1):98-106. doi: 10.1016/S1470-2045(20)30537-4. Lancet Oncol. 2021. PMID: 33387498
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
